KURA
Price
$10.65
Change
-$0.00 (-0.00%)
Updated
Oct 2 closing price
Capitalization
943.87M
27 days until earnings call
Intraday BUY SELL Signals
ZBIO
Price
$28.30
Change
+$0.36 (+1.29%)
Updated
Oct 2 closing price
Capitalization
1.8B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs ZBIO

KURA vs ZBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KURA vs. ZBIO commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and ZBIO is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
KURA vs ZBIO: Fundamental Ratings
KURA
ZBIO
OUTLOOK RATING
1..100
7175
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
5453
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (64) in the Biotechnology industry is in the same range as ZBIO (78) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

KURA's SMR Rating (99) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

ZBIO's Price Growth Rating (53) in the null industry is in the same range as KURA (54) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to KURA’s over the last 12 months.

ZBIO's P/E Growth Rating (84) in the null industry is in the same range as KURA (100) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURAZBIO
RSI
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 2 days ago
88%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 8 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (KURA: $10.65 vs. ZBIO: $27.94)
Brand notoriety: KURA and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 115% vs. ZBIO: 123%
Market capitalization -- KURA: $943.87M vs. ZBIO: $1.8B
KURA [@Biotechnology] is valued at $943.87M. ZBIO’s [@Biotechnology] market capitalization is $1.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 0 FA rating(s) are green while ZBIO’s FA Score has 0 green FA rating(s).

  • KURA’s FA Score: 0 green, 5 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, KURA is a better buy in the long-term than ZBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 3 TA indicator(s) are bullish while ZBIO’s TA Score has 4 bullish TA indicator(s).

  • KURA’s TA Score: 3 bullish, 7 bearish.
  • ZBIO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ZBIO is a better buy in the short-term than KURA.

Price Growth

KURA (@Biotechnology) experienced а -1.93% price change this week, while ZBIO (@Biotechnology) price change was +1.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

KURA is expected to report earnings on Oct 29, 2026.

ZBIO is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KURA
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DAVE339.5918.08
+5.62%
Dave
RAIN0.840.04
+4.58%
RAIN ENHANCEMENT TECHNOLOGIES HOLDCO INC
BLZE14.180.19
+1.36%
Backblaze
ED103.501.29
+1.26%
Consolidated Edison
EBMT21.280.22
+1.04%
Eagle Bancorp Montana